Research programme: small interfering RNA therapeutics - Sanegene Bio
Alternative Names: Small interfering RNA therapeutics; Small interfering RNA therapeutics - Sanegene BioLatest Information Update: 19 Sep 2023
At a glance
- Originator SanegeneBio
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Immunological disorders
- Research CNS disorders; Unspecified
Most Recent Events
- 31 Jul 2023 Early research in Unspecified in USA (Parenteral), prior to July 2023 (Sanegene Bio pipeline, July 2023)
- 31 Jul 2023 Early research in CNS disorders in USA (Parenteral), prior to July 2023 (Sanegene Bio pipeline, July 2023)
- 31 Jul 2023 Preclinical trials in Cardiovascular disorders in USA (Parenteral), prior to July 2023 (Sanegene Bio pipeline, July 2023)